Register Online | Request agenda


Event Overview
Summary: Why Attend?
Who Should Attend?
Speakers
Exclusive Event Partner
Exclusive Media Partner


Oncology Market & Patient Access

Event Overview:

Slow approval times, coupled with ballooning drug discovery and development costs, a dire macro-economic situation, and an aging population call for innovative action, when it comes to the pricing of oncology drugs, in order to secure sustainable market access.
There is an ever-growing need for innovative models, such as risk sharing, patient access and value-based pricing agreements, to obtain health technology assessor (HTA) and payer approval for drugs that threaten to be prohibitively expensive. Payer and HTA approval is necessary for financing drugs from ever-tightening budgets. Yet many hurdles still remain, when it comes to negotiating and implementing innovative agreements.
By examining the most up to date case studies in oncology reimbursement you will gain a clear understanding of not only what is required for pricing and reimbursement models, but you will also grasp what is operationally feasible.
Communicate with all stakeholders, to better analyze conflicting objectives and how they may be most successfully reconciled in order to develop the most effective and competitive market access strategy.
Without this critical information, executives will lack the tools necessary to most effectively manage the conflicting incentives of all parties involved; they will struggle under the administrative burden commonly associated with these agreements. Attend this online training and improve your pricing and reimbursement strategy; secure pharmaceutical market access for your high value oncology product.



Summary: Why Attend?


 

Who Should Attend?


 

Speakers:


 

Exclusive Event Partner:

Exclusive Media Partner: